ridm@nrct.go.th   ระบบคลังข้อมูลงานวิจัยไทย   รายการโปรดที่คุณเลือกไว้

Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy

หน่วยงาน มหาวิทยาลัยเชียงใหม่

รายละเอียด

ชื่อเรื่อง : Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy
นักวิจัย : Sirachainan N. , Nuchprayoon I. , Thanarattanakorn P. , Pakakasama S. , Lusawat A. , Visudibhan A. , Dhanachai M. , Larbcharoensub N. , Amornfa J. , Shotelersuk K. , Katanyuwong K. , Tangkaratt S. , Hongeng S.
คำค้น : -
หน่วยงาน : มหาวิทยาลัยเชียงใหม่
ผู้ร่วมงาน : -
ปีพิมพ์ : 2554
อ้างอิง : 09675868 , 2-s2.0-79952186468 , 10.1016/j.jocn.2010.08.012 , https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79952186468&origin=inward , http://cmuir.cmu.ac.th/jspui/handle/6653943832/43079
ที่มา : -
ความเชี่ยวชาญ : -
ความสัมพันธ์ : -
ขอบเขตของเนื้อหา : -
บทคัดย่อ/คำอธิบาย :

Medulloblastoma is the most common malignant brain tumor in children. Post-surgical craniospinal irradiation (CSI; 30-36 Gy) plus local boost radiation therapy (RT; 54-56 Gy) is a standard treatment for children with medulloblastoma who are over 3 years old, resulting in a 5-year overall survival (OS) rate of 46% to 65% in average-risk patients and 50% in high-risk patients. The addition of chemotherapy has the benefit of reducing complications from radiation and improving the OS rate. Using this approach, the estimated 5-year OS rates for patients with average- and high-risk medulloblastomas treated with different protocols are 65% to 85% and 16% to 70%, respectively. In this study, we determined the outcome of patients with average- and high-risk medulloblastomas treated with reduced dosage CSI and chemotherapy with an oral etoposide-based regimen. The study included 49 patients, with a mean age of 7.7 ± 3.4 years. Twenty-six patients (53%) were classified as average-risk and 23 patients (47%) as high-risk. In the average-risk group, the 5-year progression free survival (PFS) rate was 62.9% ± 10% and the 5-year OS rate was 70.4% ± 9.5%. In the high-risk group the 5-year PFS rate was 48.9% ± 13% and the 5-year OS rate was 49.7% ± 13%. In the average-risk group, patients who received CSI of either 24 Gy (n = 20) or 36 Gy (n = 9) showed no difference in their 5-year PFS and OS rates. We found that patients who were ≤10 years old and patients who were female had a significantly better 5-year PFS rate. © 2010 Elsevier Ltd. All rights reserved.

บรรณานุกรม :
Sirachainan N. , Nuchprayoon I. , Thanarattanakorn P. , Pakakasama S. , Lusawat A. , Visudibhan A. , Dhanachai M. , Larbcharoensub N. , Amornfa J. , Shotelersuk K. , Katanyuwong K. , Tangkaratt S. , Hongeng S. . (2554). Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy.
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Sirachainan N. , Nuchprayoon I. , Thanarattanakorn P. , Pakakasama S. , Lusawat A. , Visudibhan A. , Dhanachai M. , Larbcharoensub N. , Amornfa J. , Shotelersuk K. , Katanyuwong K. , Tangkaratt S. , Hongeng S. . 2554. "Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy".
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Sirachainan N. , Nuchprayoon I. , Thanarattanakorn P. , Pakakasama S. , Lusawat A. , Visudibhan A. , Dhanachai M. , Larbcharoensub N. , Amornfa J. , Shotelersuk K. , Katanyuwong K. , Tangkaratt S. , Hongeng S. . "Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy."
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ , 2554. Print.
Sirachainan N. , Nuchprayoon I. , Thanarattanakorn P. , Pakakasama S. , Lusawat A. , Visudibhan A. , Dhanachai M. , Larbcharoensub N. , Amornfa J. , Shotelersuk K. , Katanyuwong K. , Tangkaratt S. , Hongeng S. . Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ ; 2554.